Published in Cephalalgia on July 01, 2004
Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev (2010) 11.25
Migraine pathogenesis and state of pharmacological treatment options. BMC Med (2009) 1.16
Pathophysiology of migraine. Ann Indian Acad Neurol (2012) 1.14
Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med (2011) 1.13
Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling. Mol Pain (2008) 1.05
New drugs for migraine. J Headache Pain (2009) 1.02
Presynaptic facilitation of glutamate release in the basolateral amygdala: a mechanism for the anxiogenic and seizurogenic function of GluK1 receptors. Neuroscience (2012) 0.95
Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.92
The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. J Pharmacol Exp Ther (2010) 0.92
Soman induces ictogenesis in the amygdala and interictal activity in the hippocampus that are blocked by a GluR5 kainate receptor antagonist in vitro. Neuroscience (2008) 0.90
Emerging drugs for migraine prophylaxis and treatment. MedGenMed (2006) 0.88
Acute migraine: Current treatment and emerging therapies. Ther Clin Risk Manag (2007) 0.87
Migraine is a neuronal disease. J Neural Transm (Vienna) (2010) 0.86
Prophylaxis of migraine. Neuropsychiatr Dis Treat (2006) 0.84
Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev (2012) 0.84
Suppression of stretch reflex activity after spinal or systemic treatment with AMPA receptor antagonist NGX424 in rats with developed baclofen tolerance. Br J Pharmacol (2010) 0.83
Exploring kainate receptor pharmacology using molecular dynamics simulations. Neuropharmacology (2009) 0.83
Acute migraine therapy: new drugs and new approaches. Curr Treat Options Neurol (2011) 0.82
Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev (2017) 0.81
Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation. Br J Pharmacol (2009) 0.81
Kainate receptor signaling in pain pathways. Mol Pharmacol (2012) 0.81
Update on future headache treatments. Neurol Sci (2013) 0.80
Kynurenines and headache. J Neural Transm (Vienna) (2011) 0.79
Are the current IHS guidelines for migraine drug trials being followed? J Headache Pain (2010) 0.79
Effects of ionotropic glutamate receptor antagonists on rat dural artery diameter in an intravital microscopy model. Br J Pharmacol (2010) 0.79
Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives. Curr Neuropharmacol (2011) 0.78
Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration. J Pharmacol Exp Ther (2012) 0.78
Release of CGRP from mouse brainstem slices indicates central inhibitory effect of triptans and kynurenate. J Headache Pain (2014) 0.77
Receptor and channel heteromers as pain targets. Pharmaceuticals (Basel) (2012) 0.77
Medicinal chemistry of competitive kainate receptor antagonists. ACS Chem Neurosci (2010) 0.76
Metabotropic glutamate receptor 5: a target for migraine therapy. Ann Clin Transl Neurol (2016) 0.75
Neto2 Assembles with Kainate Receptors in DRG Neurons during Development and Modulates Neurite Outgrowth in Adult Sensory Neurons. J Neurosci (2017) 0.75
Current migraine management - patient acceptability and future approaches. Neuropsychiatr Dis Treat (2008) 0.75
A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study. J Neural Transm (Vienna) (2016) 0.75
An update on migraine: current understanding and future directions. J Neurol (2017) 0.75
New appendix criteria open for a broader concept of chronic migraine. Cephalalgia (2006) 5.97
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia (2010) 4.24
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia (2010) 3.54
Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med (2000) 3.26
Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis (2001) 3.06
RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol (2005) 2.96
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology (2005) 2.91
Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell (1991) 2.83
A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature (1997) 2.74
Kainate receptors are involved in synaptic plasticity. Nature (1999) 2.43
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother (2000) 2.33
A Coagulation Defect Produced by Nitrogen Mustard. Science (1948) 2.26
Synthesis and evaluation of a series of novel 2-[(4-chlorophenoxy)methyl]benzimidazoles as selective neuropeptide Y Y1 receptor antagonists. J Med Chem (1998) 2.23
Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia (2006) 2.23
Health differentials between blacks and whites: recent trends in mortality and morbidity. Milbank Q (1987) 2.19
Greater occipital nerve blockade for cluster headache. Cephalalgia (2002) 2.14
T cell awareness of paternal alloantigens during pregnancy. Science (1995) 2.12
Impaired fetal T cell development and perinatal lethality in mice lacking the cAMP response element binding protein. Proc Natl Acad Sci U S A (1998) 2.02
Triptans are all different. Arch Neurol (2001) 2.00
LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology (1998) 1.98
Measurement of striatal H2O2 by microdialysis following global forebrain ischemia and reperfusion in the rat: correlation with the cytotoxic potential of H2O2 in vitro. Brain Res (1995) 1.93
Autoimmune diabetes as a consequence of locally produced interleukin-2. Nature (1992) 1.92
Premonitory symptoms in migraine: an electronic diary study. Neurology (2003) 1.81
Hemicrania continua is not that rare. Neurology (2001) 1.78
Cytolytic T cells recognize the two amino-terminal domains of H-2 K antigens in tandem in influenza A infected cells. Cell (1984) 1.77
Idiopathic intracranial hypertension without papilledema. Arch Neurol (1991) 1.76
Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Infect Immun (2001) 1.75
The Henry Ford Hospital Headache Disability Inventory (HDI). Neurology (1994) 1.72
Low brain magnesium in migraine. Headache (1989) 1.70
Complete nucleotide sequence of the murine H-2Kk gene. Comparison of three H-2K locus alleles. Nucleic Acids Res (1984) 1.70
Proposals for new standardized general diagnostic criteria for the secondary headaches. Cephalalgia (2009) 1.68
Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest (1999) 1.64
Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet (2001) 1.63
Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis (2001) 1.63
Calcium buffering properties of calbindin D28k and parvalbumin in rat sensory neurones. J Physiol (1993) 1.58
AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology (1998) 1.57
The corneal endothelium and the spectrum of essential iris atrophy. Am J Ophthalmol (1978) 1.53
Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study. Neurology (2007) 1.51
Alloreactive cytolytic T-cell clones preferentially recognize conformational determinants on histocompatibility antigens: analysis with genetically engineered hybrid antigens. Proc Natl Acad Sci U S A (1985) 1.49
Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science (1994) 1.44
Hemicrania continua: who responds to indomethacin? Cephalalgia (2009) 1.44
Non-deletional mechanisms of peripheral and central tolerance: studies with transgenic mice with tissue-specific expression of a foreign MHC class I antigen. Immunol Rev (1991) 1.43
Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Headache (2001) 1.43
Clonal deletion of autospecific B lymphocytes. Immunol Rev (1991) 1.42
NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol (2001) 1.42
[Structure and process quality of multimodal pain therapy. Results of a survey of pain therapy clinics]. Schmerz (2012) 1.41
Headache in ischemic cerebrovascular disease. Part I: Clinical features. Cephalalgia (1992) 1.41
Enforced Bcl-2 expression inhibits antigen-mediated clonal elimination of peripheral B cells in an antigen dose-dependent manner and promotes receptor editing in autoreactive, immature B cells. J Exp Med (1997) 1.41
[Cartilage-specific autoimmunity in otosclerosis]. HNO (1993) 1.40
Environmental stress-corrosion cracking of fiberglass: lessons learned from failures in the chemical industry. J Hazard Mater (2006) 1.38
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology (2011) 1.36
Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia (2002) 1.32
Distinct mechanisms of extrathymic T cell tolerance due to differential expression of self antigen. Int Immunol (1992) 1.32
Chronic daily headache in a tertiary care population: correlation between the International Headache Society diagnostic criteria and proposed revisions of criteria for chronic daily headache. Cephalalgia (2002) 1.30
Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia (2009) 1.29
Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache (1994) 1.28
Peripheral tolerance as a multi-step mechanism. Immunol Rev (1993) 1.27
A critical role of a facilitatory presynaptic kainate receptor in mossy fiber LTP. Neuron (2001) 1.27
The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity. Neuropharmacology (1998) 1.25
Primary chronic daily headache and its subtypes in adolescents and adults. Neurology (2004) 1.25
Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment. Eur J Immunol (1998) 1.24
Isolation of interleukin 2-induced immediate-early genes. Proc Natl Acad Sci U S A (1993) 1.23
Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Science (1998) 1.23
Transcranial magnetic stimulation confirms hyperexcitability of occipital cortex in migraine. Neurology (1998) 1.22
The results of retinal detachment surgery. Analysis of 268 operations with a broad scleral buckle. Arch Ophthalmol (1971) 1.22
The nociceptive flexion reflex in humans -- review article. Pain (2002) 1.21
A con A-stimulated T-cell hybridoma releases factors affecting haematopoietic colony-forming cells and B-cell antibody responses. Nature (1980) 1.21
The International Classification of Headache Disorders revised criteria for chronic migraine—field testing in a headache specialty clinic. Cephalalgia (2007) 1.20
Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: a randomised comparative study. J Neurol Neurosurg Psychiatry (2007) 1.20
Chronic migraine is an earlier stage of transformed migraine in adults. Neurology (2005) 1.20
[Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the Barmer health insurance (BEK) from 2008-2009]. Schmerz (2011) 1.19
The properties of intracellular calcium stores in cultured rat cerebellar neurons. J Neurosci (1991) 1.19
Migraine prophylaxis with divalproex. Arch Neurol (1995) 1.18
An interleukin-2 signal relieves BSAP (Pax5)-mediated repression of the immunoglobulin J chain gene. Immunity (1996) 1.18
Mechanism of presynaptic inhibition by neuropeptide Y at sympathetic nerve terminals. Nature (1993) 1.18
Regulation of human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a). J Immunol (1999) 1.16
[3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. J Pharmacol Exp Ther (2001) 1.16
Bioethicists' statement on the U.S. Supreme Court's Cruzan decision. N Engl J Med (1990) 1.15
Differential expression of a gene signature for scavenger/lectin receptors by endothelial cells and macrophages in human lymph node sinuses, the primary sites of regional metastasis. J Pathol (2006) 1.14
Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry (2001) 1.14
The role of nerve growth factor in the ramification of sympathetic nerve fibres into the rat iris in organ culture. J Neurochem (1972) 1.13
Menstrual cycle and headache in a population sample of migraineurs. Neurology (2000) 1.12
Biochemical characterization of CD1d expression in the absence of beta2-microglobulin. J Biol Chem (1999) 1.12
Headache disability inventory (HDI): short-term test-retest reliability and spouse perceptions. Headache (1995) 1.11
Olfactory aura in migraine. N Engl J Med (1985) 1.10
Cross-resistance to Bacillus thuringiensis toxin Cry1Ja in a strain of diamondback moth adapted to artificial diet. J Invertebr Pathol (2000) 1.10
Migraine and adiponectin: is there a connection? Cephalalgia (2007) 1.10
Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes. Cephalalgia (2004) 1.10
Intracranial tuberculomas and the CAT scan. Acta Neurochir (Wien) (1978) 1.09